Skip to content
Menu

Marker Therapeutics, Inc. MRKR

Full chart Compare
Set alert

Price alert · MRKR

All alert types
1.09 USD -0.23 (-17.42%)

Regular-session close

1.01 -0.08 -7.17%

After hours · Nov 20, 7:55 PM ET

1.09 Day range 1.45
0.81 52-week range 2.46
YTD
-26.85%
1 year
+10.10%

5D +0.39 (+42.12%)

0.7511.251.50FriMonTueWedThu1.32
Market cap
18.17M
Revenue (ttm)
3.73M
Profit margin
-278.22%
EPS (ttm)
-0.39
Shares out
8.92M
Forward P/E
-2.34
YTD return
-26.85%
1-year return
+10.10%
50-day average
3.71
Volume
1.97M
Avg volume
683.93K
Open
1.34
Previous close
1.32
Day's range
1.09 – 1.45
52-week range
0.81 – 2.46
Beta
1.49
Analysts
Strong Buy
Price target
19.00 (+1643.1%)

Key statistics

200-day average
3.97
Enterprise value
19.59M
Price / sales
8.19
Price / book
2.16
Revenue growth
53.30%
Free cash flow
-7.40M
Total cash
7.80M
Return on equity
-71.74%
Short % of float
1.09%

Fundamental scorecard

8 of 25 checks passed on MRKR’s reported financials

ValueGrowthProfitabilityHealthDividend

8of 25 checks passed

  • Value 0 of 5
  • Growth 2 of 5
  • Profitability 1 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
MRKR Revenue — quarterly 0
MRKR Net income — quarterly -1.84M
MRKR EPS — quarterly -0.10

Earnings

MRKR recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 20240.00-0.26——
Aug 14, 2024Jun 1, 20240.00-0.25——
May 15, 2024Mar 1, 20240.00-0.27——
Mar 27, 2024Dec 1, 20230.00———
Nov 9, 2023Sep 1, 20230.00-0.34——
Aug 14, 2023Jun 1, 20230.00-0.47——

Upgrades / downgrades

MRKR analyst upgrades and downgrades
DateFirmActionFromTo
Apr 30, 2024Ladenburg Thalmanninit—Buy

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on MRKR — it syncs with the Stock Master app.

Institution ownership

MRKR institution ownership
Holder% heldSharesValueReported
NEA Management Company, LLC12.01%1,071,4283.66MSep 29, 2024
Aisling Capital Management LP3.52%314,2861.07MSep 29, 2024
Vanguard Group Inc2.72%243,122831.48KSep 29, 2024
AR Asset Management, Inc.0.83%73,700252.05KSep 29, 2024
Geode Capital Management, LLC0.80%71,561244.74KSep 29, 2024
Renaissance Technologies, LLC0.45%39,750135.94KSep 29, 2024

Fund ownership

MRKR fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.72%153,473524.88KSep 29, 2024
Vanguard Extended Market Index Fund0.98%87,137298.01KSep 29, 2024
Fidelity Extended Market Index Fund0.45%39,946136.62KOct 30, 2024
iShares Micro Cap ETF0.19%16,57956.70KOct 30, 2024
DFA U.S. Small Cap Series0.18%15,90054.38KJul 30, 2024
Fidelity Total Market Index Fund0.14%12,81143.81KOct 30, 2024